Going forward, DOCOMO will continue to strengthen its cooperation with global partners under the OREX brand to make Open RAN a reality. 1 KT Corporation, ...

Orexigen Weight-Loss Pill Dinged by FDA: What Next for Contrave? By David W Freeman February 1, 2011 / 12:15 PM EST / CBS News ...

2012 ushered in a new era in weight-loss drugs, with the FDA’s reversal on treatments such as Vivus Pharmaceutical’s Qsymia and Arena’s Belviq, but a potential competitor’s recent success may shake up ...

OREX data by YCharts What : Shares of the anti-obesity drugmaker Orexigen Therapeutics lost nearly a quarter of their value in September based on.

Since introducing the OREX ® brand in February 2023, DOCOMO has been supporting Open RAN verifications for global telecom operators to help realize more open mobile networks around the world.

HAUPPAUGE, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal ...

SAN DIEGO, March 30, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) ... In Europe, the medicine was approved in March 2015 with the brand name Mysimba.

SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an ...

Orexigen Therapeutics, Inc. (OREX) Q3 2017 Earnings Conference Call November 13, 2017 5:00 PM ETExecutivesJason Keyes - SVP & CFO Michael Narachi -... Skip to content Home page Seeking Alpha ...

But the question for Contrave's maker, Orexigen, and its marketing partner, the Japanese drug giant Takeda, is whether even grabbing the biggest share of the weight-loss drug market will be enough.

OREX is DOCOMO's Open RAN service brand, developed in collaboration with multiple global vendors. It can be customized to address the unique challenges of each customer. The introduction of OREX Open ...